<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39196">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596126</url>
  </required_header>
  <id_info>
    <org_study_id>633765</org_study_id>
    <secondary_id>2015-002868-17</secondary_id>
    <nct_id>NCT02596126</nct_id>
  </id_info>
  <brief_title>Secondary Prevention of Cardiovascular Disease in the Elderly Trial</brief_title>
  <acronym>SECURE</acronym>
  <official_title>Secondary Prevention of Cardiovascular Disease in the Elderly Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General University Hospital, Prague</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio Madrileño de Salud, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Di Ricerche Farmacologiche Mario Negri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of a polypill strategy containing
      aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the
      standard of care (usual care according to the local clinical practices at each participating
      country) in secondary prevention of major cardiovascular events (cardiovascular death,
      nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in
      elderly patients with a recent myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total number of 3206 patients will be randomized (1:1) to treatment arms. Patients will be
      recruited across seven countries in Europe (Spain, Italy, Germany, France, Hungary, Poland,
      and Czech Republic).

      Patients will be ≥65 years old and diagnosed with a type 1 myocardial infarction within 8
      weeks prior to study enrolment.

      Once the inclusion and exclusion criteria are confirmed, patients will be included in the
      study after signing informed consent.

      Randomization will take place within 8 weeks of the index event (AMI type I) in a 1:1 ratio
      to one of the two arms:

        -  Cardiovascular Polypill (containing Aspirin, Ramipril, and Atorvastatin)

        -  Usual care

      Patients will be followed up for a minimum of 2 years and a maximum of 4 years.

      There will be 3 follow up visits at month 6, 12 and 24 and telephone follow up calls at
      month 18, 36 and 48
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the occurrence of Major Adverse Cardiovascular Events (MACE) between the Cardiovascular Combination Polypill AAR and the Standard of Care Treatment</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of the first occurrence of any component of the following composite endpoint: CV death, MI, stroke.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the first occurrence of the individual components of the primary endpoint</measure>
    <time_frame>24 months</time_frame>
    <description>CV death.
Nonfatal type 1 myocardial infarction.
Nonfatal ischemic stroke.
Urgent coronary revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Treatment Adherence</measure>
    <time_frame>24 months</time_frame>
    <description>The Morisky-Medication Adherence Scale (8 item) Questionnaire will be administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Satisfaction</measure>
    <time_frame>24 months</time_frame>
    <description>The treatment Satisfaction Questionnaire for Medication (TSQM) will be administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic and Diastolic Blood Pressure (SBP and DBP)</measure>
    <time_frame>24 months</time_frame>
    <description>Systolic and diastolic blood pressure will be collected and summarized at each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL cholesterol level</measure>
    <time_frame>24 months</time_frame>
    <description>Non-fasting blood analysis will be collected and LDL cholesterol level evaluated at each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional differences in performance of the polypill in the previous endpoints</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economic Evaluation Comparing Intervention and Usual Care Arm</measure>
    <time_frame>24 months</time_frame>
    <description>Cost differences and Incremental Cost-Effectiveness Ratio (ICER) will be assessed at each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>24 months</time_frame>
    <description>The European Quality of Life- 5 Dimensions (EQ-5D) Questionnaire will be administered at each timepoint to evaluate change in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>24 months</time_frame>
    <description>All-cause mortality and adverse events (bleeding, renal dysfunction, drug, allergies, and refractory cough leading to drug discontinuation).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3206</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Prevention for Secondary CV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiovascular Polypill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cardiovascular Polypill</intervention_name>
    <description>Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.
Participants will receive one of the following cardiovascular polypill:
(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).
or
(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).</description>
    <arm_group_label>Cardiovascular Polypill</arm_group_label>
    <other_name>Polypill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment Prevention for Secondary CV</intervention_name>
    <description>ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.</description>
    <arm_group_label>Treatment Prevention for Secondary CV</arm_group_label>
    <other_name>Antiplatelet agents</other_name>
    <other_name>Lipid Lowering Agents</other_name>
    <other_name>Renin-angiotensin-aldosterone system blockers</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with a type 1 myocardial infarction within the previous 8 weeks.

          2. Subjects must be ≥65 years old, presenting with at least one of the following
             additional conditions:

               -  Documented diabetes mellitus or previous treatment with oral hypoglycemic drugs
                  or insulin.

               -  Mild to moderate renal dysfunction: creatinine clearance 60-30 mL/min/1.73 m2.

               -  Prior myocardial infarction: defined as an AMI occurring before the index event
                  documented in a medical report.

               -  Prior coronary revascularization: coronary artery bypass grafting (CABG) or
                  percutaneous coronary intervention (PCI).

               -  Prior stroke: history of a documented stroke, defined as an acute episode of
                  focal cerebral, spinal, or retinal dysfunction caused by infarction of central
                  nervous system tissue, not resulting in death.

               -  Age ≥ 75 years.

          3. Signing informed consent.

        Exclusion Criteria:

          1. Unable to sign informed consent.

          2. Contraindications to any of the components of the polypill.

          3. Living in a nursing home.

          4. Mental illness limiting the capacity of self-care.

          5. Participating in another clinical trial.

          6. Severe congestive heart failure (NYHA III-IV).

          7. Severe renal disease (Creatinine Clearance (CrCl) &lt;30ml/min/1.73 m2).

          8. Need for oral anticoagulation at the time of randomization or planned in the future
             months.

          9. Any condition limiting life expectancy &lt;2 years, including but not limited to active
             malignancy.

         10. Significant arrhythmias (including unresolved ventricular arrhythmias or atrial
             fibrillation).

         11. Scheduled coronary revascularization (patients can be randomized after final
             revascularization is completed within the prespecified timeframe).

         12. Do not agree to the filing, forwarding and use of his/ her pseudonymised data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentin Fuster, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Nacional de Investigaciones Cardiovasculares Carlos III</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Maria Castellano Vazquez, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centro Nacional de Investigaciones Cardiovasculares Carlos III</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Maria Castellano Vazquez, MD, PhD</last_name>
    <email>josemaria.castellano@cnic.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ester Cunha Pavon</last_name>
    <email>ecunha@cnic.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fakultní nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha</city>
        <state>Praha 10</state>
        <zip>10034</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>František Bednář, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Praha</city>
        <state>Praha 10</state>
        <zip>15030</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Petr Neužil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Všeobecná fakultní nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <state>Praha</state>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aleš Linhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Claude Lubanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Rudolfa a Stefanie Benešov</name>
      <address>
        <city>Benešov</city>
        <zip>25601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Filip Kratochvíl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zdeněk Klimsa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miloš Táborský, MD, CSc, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Slaný</name>
      <address>
        <city>Slaný</city>
        <zip>27401</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ondřej Čermák, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>François Schiele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Park Berlin Humboldtmühle</name>
      <address>
        <city>Berlin - Tegel</city>
        <state>Berlin</state>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Heinz Theres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Mueller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik am See, Rehabilitationszentrum für innere Medizin</name>
      <address>
        <city>Rüdersdorf</city>
        <state>Brandenburg</state>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Heinz Voeller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergej Belozerov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Centrum für Schlaganfallforschung (CSB)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wolfram Döhner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadja Scherbakov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brandenburgklinik Berlin-Brandenburg GmbH, Haus Brandenburg/ Kardiologie</name>
      <address>
        <city>Bernau-Waldsiedlung</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Schikora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Hemeling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Városmajori Szív- és Érgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Béla Merkely, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST degli Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pompilio Faggiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale di Zona-Ospedale Valduce</name>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giovanni Corrado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST di Monza-Presidio Ospedaliero di Desio</name>
      <address>
        <city>Desio</city>
        <zip>20832</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fausto Avanzini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Policlinico di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Federico Lombardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paola Montanari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Rho Dense di Passirana</name>
      <address>
        <city>Passirana-rho</city>
        <zip>20017</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marco D Veniani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Frisinghelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Ss Giovanni di Dio e Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Federico PISCIONE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST di Bergamo Ovest-Ospedale Treviglio</name>
      <address>
        <city>Treviglio</city>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo SGANZERLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Wielospecjalistyczny im. Dr. Ludwika Błażka w Inowrocławiu</name>
      <address>
        <city>Inowrocław</city>
        <zip>88100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marek Bronisz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zespół Opieki Zdrowotnej w Kłodzku</name>
      <address>
        <city>Kłodzko</city>
        <zip>57-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Piotr Berkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny w Legnicy</name>
      <address>
        <city>Legnica</city>
        <zip>59220</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Barbara Engel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Szpital im. Dra Alfreda Sokołowskiego</name>
      <address>
        <city>Wałbrzych</city>
        <zip>58309</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roman Szełemej, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Kardiologiczne &quot;Pro Corde&quot; Sp. z o.o.</name>
      <address>
        <city>Wrocław</city>
        <zip>50315</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bartosz Szafran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ we Wrocławiu</name>
      <address>
        <city>Wrocław</city>
        <zip>50981</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Piotr Ponikowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zespół Opieki Zdrowotnej w Świdnicy</name>
      <address>
        <city>Świdnica</city>
        <zip>58100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bartomiej Janiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio F Ortiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Borja C Ibanez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roberto M Asenjo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://secure-h2020.eu/</url>
    <description>SECURE Clinical Trial Website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 3, 2017</lastchanged_date>
  <firstreceived_date>October 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polypill</keyword>
  <keyword>Prevention of Secondary Cardiovascular Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Cardiovascular Combination Polypill AAR</keyword>
  <keyword>Cardiovascular Disease in the Elderly</keyword>
  <keyword>Adherence</keyword>
  <keyword>SECURE</keyword>
  <keyword>Elderly</keyword>
  <keyword>Secondary Cardiovascular Disease</keyword>
  <keyword>Secondary Cardiovascular Prevention</keyword>
  <keyword>Randomized Cardiovascular Trial</keyword>
  <keyword>Randomized Trial</keyword>
  <keyword>Cardiovascular Polypill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
